Academic Research Consortium High Bleeding Risk Criteria associated with 2-year bleeding events and mortality after transcatheter aortic valve replacement discharge: a Japanese Multicentre Prospective OCEAN-TAVI Registry Study

Abstract Aims To investigate the ability of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria and ARC-HBR score to predict 2-year bleeding and mortality in patients undergoing transcatheter aortic valve replacement (TAVR). Methods and results We enrolled 2514 patients who underwent successful TAVR during 2013–17. In this study, we used the ARC-HBR score for further HBR-risk stratification, and the ARC-HBR score was calculated as follows: each major criterion was 2 points and each minor criterion was 1 point. The impact of the ARC-HBR criteria and increasing ARC-HBR score on the incidence of moderate/severe bleeding events, mortality, and ischaemic stroke in the first 2 years were evaluated. We used survival classification and regression tree (CART) analysis for 2-year moderate or severe bleeding events, and patients were statistically classified into HBR low- (ARC-HBR score ≤1), intermediate- (ARC-HBR score = 2–4), or high-risk (ARC-HBR score ≥5) groups, and 91.4% were at HBR (ARC-HBR score ≥2). The rates of 2-year moderate/severe bleeding events and all-cause mortality were higher in the ARC-HBR group and highest in the HBR high-risk group. An increased HBR score was significantly associated with moderate/severe bleeding events [hazard ratio (HR) 1.19, 95% confidence interval (CI) 1.07–1.31; P = 0.001] and all-cause mortality (adjusted HR 1.24, 95% CI 1.17–1.32; P < 0.001). Conclusions The ARC-HBR criteria identify patients at HBR after TAVR; an increased ARC-HBR score is associated with 2-year moderate/severe bleeding events and mortality.

[1]  J. Peper,et al.  Assessment of the Academic Research Consortium for High Bleeding Risk Criteria in Patients Undergoing TAVR. , 2021, JACC. Cardiovascular interventions.

[2]  Masato Nakamura,et al.  Implications and characteristics of high bleeding risk in East Asian patients undergoing percutaneous coronary intervention: Start with what is right rather than what is acceptable. , 2020, Journal of cardiology.

[3]  P. Stella,et al.  Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. , 2020, The New England journal of medicine.

[4]  K. Tanabe,et al.  High Bleeding Risk and Clinical Outcomes in East Asian Patients Undergoing Percutaneous Coronary Intervention: the PENDULUM Registry. , 2020, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[5]  Samin K. Sharma,et al.  Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients. , 2020, Journal of the American College of Cardiology.

[6]  P. Stella,et al.  Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. , 2020, The New England journal of medicine.

[7]  A. Ramzy,et al.  Transcatheter aortic valve replacement in patients with severe aortic stenosis and active cancer: a systematic review and meta-analysis , 2020, Open Heart.

[8]  W. Harmsen,et al.  Long‐Term Outcomes After Transcatheter and Surgical Aortic Valve Replacement in Patients With Cirrhosis: A Guide for the Hepatologist , 2020, Hepatology.

[9]  J. Tijssen,et al.  A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. , 2019, The New England journal of medicine.

[10]  M. Toyofuku,et al.  Application of the Academic Research Consortium High Bleeding Risk Criteria in an All-Comers Registry of Percutaneous Coronary Intervention. , 2019, Circulation. Cardiovascular interventions.

[11]  A. Colombo,et al.  Thrombotic Versus Bleeding Risk After Transcatheter Aortic Valve Replacement: JACC Review Topic of the Week. , 2019, Journal of the American College of Cardiology.

[12]  Angelo B. Biviano,et al.  Antithrombotic Therapy and Cardiovascular Outcomes After Transcatheter Aortic Valve Replacement in Patients With Atrial Fibrillation. , 2019, JACC. Cardiovascular interventions.

[13]  H. Okayama,et al.  Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. , 2019, JAMA.

[14]  M. Price,et al.  Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention , 2019, Circulation.

[15]  J. Leipsic,et al.  Transcatheter Aortic‐Valve Replacement with a Balloon‐Expandable Valve in Low‐Risk Patients , 2019, The New England journal of medicine.

[16]  Andrew S. Mugglin,et al.  Transcatheter Aortic‐Valve Replacement with a Self‐Expanding Valve in Low‐Risk Patients , 2019, The New England journal of medicine.

[17]  Deepak L. Bhatt,et al.  Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting. , 2019, Journal of the American College of Cardiology.

[18]  J. Eikelboom,et al.  Blood Disorders in Patients Undergoing Transcatheter Aortic Valve Replacement: A Review. , 2019, JACC. Cardiovascular interventions.

[19]  Deepak L. Bhatt,et al.  Racial Differences in Ischaemia/Bleeding Risk Trade-Off during Anti-Platelet Therapy: Individual Patient Level Landmark Meta-Analysis from Seven RCTs , 2018, Thrombosis and Haemostasis.

[20]  K. Takagi,et al.  Transcatheter aortic valve replacement outcomes in Japan: Optimized CathEter vAlvular iNtervention (OCEAN) Japanese multicenter registry. , 2019, Cardiovascular revascularization medicine : including molecular interventions.

[21]  K. Takagi,et al.  Elevation of B‐Type Natriuretic Peptide at Discharge is Associated With 2‐Year Mortality After Transcatheter Aortic Valve Replacement in Patients With Severe Aortic Stenosis: Insights From a Multicenter Prospective OCEAN‐TAVI (Optimized Transcatheter Valvular Intervention–Transcatheter Aortic Valve , 2017, Journal of the American Heart Association.

[22]  S. Kohsaka,et al.  Impact of the Clinical Frailty Scale on Outcomes After Transcatheter Aortic Valve Replacement , 2017, Circulation.

[23]  Deepak L. Bhatt,et al.  Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials , 2017, The Lancet.

[24]  R. Smalling,et al.  The Society of Thoracic Surgery Risk Score as a Predictor of 30-Day Mortality in Transcatheter vs Surgical Aortic Valve Replacement: A Single-Center Experience and its Implications for the Development of a TAVR Risk-Prediction Model. , 2017, The Journal of invasive cardiology.

[25]  John D Carroll,et al.  2016 Annual Report of The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. , 2017, The Annals of thoracic surgery.

[26]  C. Held,et al.  Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial , 2016, European heart journal.

[27]  M. Mack,et al.  Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. , 2016, The New England journal of medicine.

[28]  Sean M. O'Brien,et al.  Development and Validation of a Risk Prediction Model for In-Hospital Mortality After Transcatheter Aortic Valve Replacement. , 2016, JAMA cardiology.

[29]  Peter L Duffy,et al.  Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention. , 2015, Journal of the American College of Cardiology.

[30]  S. Windecker,et al.  Stable coronary artery disease: revascularisation and invasive strategies , 2015, The Lancet.

[31]  A. Go,et al.  Association of spontaneous bleeding and myocardial infarction with long-term mortality after percutaneous coronary intervention. , 2015, Journal of the American College of Cardiology.

[32]  M. Mack,et al.  Incidence, predictors, and prognostic impact of late bleeding complications after transcatheter aortic valve replacement. , 2014, Journal of the American College of Cardiology.

[33]  Braunwald,et al.  Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. , 2014, The New England journal of medicine.

[34]  Pascal Leprince,et al.  Predictive factors of early mortality after transcatheter aortic valve implantation: individual risk assessment using a simple score , 2014, Heart.

[35]  A. Kirtane,et al.  Incidence and effect of acute kidney injury after transcatheter aortic valve replacement using the new valve academic research consortium criteria. , 2013, The American journal of cardiology.

[36]  Stuart J Pocock,et al.  Transcatheter versus surgical aortic-valve replacement in high-risk patients. , 2011, The New England journal of medicine.

[37]  S. Pocock,et al.  Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. , 2010, The New England journal of medicine.

[38]  Wansu Chen,et al.  Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. , 2007, Journal of the American College of Cardiology.

[39]  T. Yamaguchi Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation : a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. , 2000, Stroke.

[40]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.